Urticaria Clinical Trial
Official title:
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients
Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg
(Xyzal®) once daily in the treatment of patients with CIU over 6 weeks.
Trial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
Primary end point: To evaluate the change in average AM/PM reflective pruritus score from
baseline recorded in the subjects’ diaries during the first two weeks of the treatment.
Secondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin®) and
levocetirizine 5mg (Xyzal®) once daily in the treatment of subjects with CIU over 6 weeks.
Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg
(Xyzal®) once daily in the treatment of patients with CIU over 6 weeks.
Trial design: Randomized, Double-Blind, Active-Controlled, Parallel-Group Study.
Primary endpoint: To evaluate the change in average AM/PM reflective pruritus score from
baseline recorded in the subjects’ diaries during the first two weeks of the treatment.
Secondary Objectives: To assess the efficacy and safety of desloratadine 5mg (Denosin®) and
levocetirizine 5mg (Xyzal®) once daily in the treatment of subjects with CIU over 6 weeks.
Primary endpoint:
To evaluate the change in average AM/PM reflective pruritus score from baseline recorded in
the patient diaries during the first two weeks of treatment
Secondary Endpoints- To evaluate the change in average AM/PM reflective pruritus score from
baseline recorded in the subjects’ diaries over the 6 weeks.
To evaluate the reflective average AM/PM scores for number of hives, size of largest hive,
and total symptom score (sum of pruritus, number of hives, and size of largest hive scores).
Average individual AM/PM instantaneous scores for pruritus, number of hives, and size of
largest hive are also evaluated.
AM instantaneous scores for pruritus, number of hives, and size of largest hive are also
evaluated.
PM instantaneous scores for pruritus, number of hives, and size of largest hive are also
evaluated.
PM reflective scores for pruritus, number of hives, and size of largest hive are also
evaluated.
The interference with sleep (AM reflective), and interference with daily activities (PM
reflective) are other secondary efficacy outcomes.
Therapeutic response will be evaluated at visit 3~5.
Safety will be evaluated including vital signs are recorded at all visits, whereas sleep
latency using Epworth Sleepiness Scale (ESS) questionnaire and Visual analogue Scale (VAS)
are scored at visit 2~5. Stanford Sleepiness Scale (SSS) are scored according to the
instructions of diary cards at all visits. All adverse events are recorded and graded for
severity at visit 2~5.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03693625 -
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
|
Phase 2 | |
| Recruiting |
NCT03545464 -
COrticosteroids in acUte uRticAria in emerGency dEpartment
|
Phase 3 | |
| Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
| Not yet recruiting |
NCT00163839 -
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
|
N/A | |
| Terminated |
NCT00069329 -
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
|
N/A | |
| Completed |
NCT00876369 -
Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
|
||
| Terminated |
NCT00199238 -
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
|
Phase 2 | |
| Completed |
NCT02576041 -
Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria
|
Phase 4 | |
| Completed |
NCT00724698 -
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
|
||
| Completed |
NCT02238249 -
Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria
|
N/A | |
| Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
| Completed |
NCT03296358 -
Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.
|
N/A | |
| Completed |
NCT00130234 -
Effect of Anti-IgE in Chronic Urticaria
|
Phase 2 | |
| Completed |
NCT00795158 -
How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)
|
Phase 3 | |
| Completed |
NCT00368823 -
A Trial of Point of Care Information in Ambulatory Pediatrics
|
Phase 3 | |
| Completed |
NCT02424799 -
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
|
Phase 1 | |
| Completed |
NCT01371877 -
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
|
N/A | |
| Completed |
NCT00751218 -
A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)
|
Phase 4 | |
| Completed |
NCT03137069 -
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
|
Phase 2 | |
| Recruiting |
NCT05115136 -
Using Doxepin for Urticaria
|
Phase 3 |